SX-682 in Combination With TriAdeno Vaccine Regimen and M7824 (TGF-b "Trap/PDLi; Bintrafusp Alpha) in Advanced Solid Tumors (STAT)

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With TriAdeno Vaccine Regimen and M7824 (TGF-b "Trap/PDLi; Bintrafusp Alpha) in Advanced Solid Tumors (STAT): Conditions:   Metastatic Cancer;   Solid Tumors

Interventions:   Drug: SX-682;   Drug: M7824;   Biological: MVA-BN-CV301;   Biological: FPV-CV301

Sponsor:   National Cancer Institute (NCI)

Not yet recruiting